Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”) of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock performance was -5.40% in last session and finished the day at $53.74. Traded volume was 1,222,609 million shares in the last session and the average volume of the stock remained 775.30 million shares. The beta of the stock remained 1.12. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) insider ownership is 12.63%.

Insys Therapeutics (NASDAQ:INSY) was upgraded by research analysts at EVA Dimensions from a “hold” rating to an “overweight” rating in a report released on Wednesday, reports. Insys Therapeutics Inc (NASDAQ:INSY) dropped -8.94 percent to $75.92 yesterday on volume of 764,419.00 million shares. The intra-day range of the stock was $75.60 to $85.00. Insys Therapeutics Inc (NASDAQ:INSY) has a market capitalization of $1.63million.

Jefferson Research upgraded shares of NPS Pharmaceuticals (NASDAQ:NPSP) from a sell rating to a hold rating in a report released on Friday, Stock Ratings News reports. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)’s stock on Mar 5, 2014 reported a decrease of -5.14% to the closing price of $33.79. Its fifty two weeks range is $33.69 -$35.69. The total market capitalization recorded $3.47 billion. The overall volume in the last trading session was 2,499,385 million shares. In its share capital, NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has 102.90 million outstanding shares.

XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, provided an update on its gevokizumab development program. Based on results from the Company’s Phase 2 program in patients with erosive osteoarthritis of the hand (EOA), XOMA does not intend to launch pivotal development for the broad EOA indication. On Wednesday, shares of XOMA Corp (NASDAQ:XOMA) dropped -27.75% to close the day at $6.82. Company return on investment (ROI) is -90.30% and its monthly performance is recorded as -4.21%. XOMA Corp (NASDAQ:XOMA) quarterly revenue growth is 16.78%.